Bliss GVS Pharma (506197) Q3 25/26 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, were approved and released, with a limited review by auditors yielding unmodified conclusions.

• An interim dividend of 0.50 paisa per equity share was declared for FY 2025-26, with a record date set for February 18, 2026.

Financial highlights

• Standalone revenue from operations for the quarter ended December 31, 2025, was ₹16,468.07 lakh; consolidated revenue was ₹21,825.19 lakh.

• Standalone net profit for the quarter was ₹1,860.71 lakh; consolidated net profit was ₹2,477.91 lakh.

• For the nine months ended December 31, 2025, standalone net profit was ₹6,445.19 lakh; consolidated net profit was ₹9,772.90 lakh.

• Basic EPS for the quarter was 1.76 (standalone) and 2.20 (consolidated); for nine months, 6.11 (standalone) and 8.86 (consolidated).

Outlook and guidance

• The company continues to monitor regulatory changes, especially regarding the new Labour Codes, and will adjust accounting as needed.